Vir Biotechnology, Inc. - Common Stock (VIR)

CUSIP: 92764N102

Q3 2022 13F Holders as of 30 Sep 2022

Holder snapshot 7 signals
Share change
+675,901
Put/Call ratio
96%
SEC-reported price per share
$19.28
Number of holders
208
Value change
-$11,606,508
Number of buys
129
Open additional details 1 more signal available
Number of sells
79
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
168,594,202

Security key

92764N102

Report period

Q3 2022

Institutions

208

Top holders

10

Ownership snapshot

Top reported holders of VIR - Vir Biotechnology, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ARCH Venture Partners IX,...
Disclosed value leader
SB INVESTMENT ADVISERS (U...
Comparable rows
0/15
Latest evidence
02 Sep 2022
3/4/5 13F Highest disclosed value: $565,858,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

SB INVESTMENT ADVISERS (UK) LTD has the largest disclosed position value at $565.86M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens SB INVESTMENT ADVISERS (UK) LTD's linked filing trail.
Disclosed position value Top 5
ARCH Venture Partners IX, LLC $140.3K
SB INVESTMENT ADVISERS (UK) LTD $565.86M
BlackRock Finance, Inc. $326.31M
VANGUARD GROUP INC $208.78M
Temasek Holdings (Private) Ltd $142.7M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ARCH Venture Partners IX, LLC
3/4/5
10%+ Owner
—
denominator unverified
$140,347
91,730 shares
— 02 Sep 2022
SB INVESTMENT ADVISERS (UK) LTD
13F
Company
13F
—
denominator unverified
$565,858,000
22,216,644 shares
— 30 Jun 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$326,313,000
12,811,690 shares
— 30 Jun 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$208,784,000
8,197,244 shares
— 30 Jun 2022
Temasek Holdings (Private) Ltd
13F
Company
13F
—
denominator unverified
$142,697,025
5,602,553 shares
— 30 Jun 2022
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$140,572,000
5,519,138 shares
— 30 Jun 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
208
Shares
86,915,381
Rows available
208
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2022 vs Q2 2022 Across Filers

Q2 2022 holders
201
Q3 2022 holders
208
Holder diff
7
Investor Q2 2022 Shares Q3 2022 Shares Share Diff Share Chg % Q2 2022 value Q3 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .